Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Jasper Therapeutics Q2 2024 GAAP EPS $(0.97) Beats $(1.08) Estimate; Cash $106.8M

Author: Benzinga Newsdesk | August 13, 2024 07:17am
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.08) by 10.19 percent. This is a 34.01 percent increase over losses of $(1.47) per share from the same period last year.

Posted In: JSPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist